Asceneuron SA Secures $100 Million in Series C Funding for Breakthrough Neurodegenerative Therapeutics

Asceneuron SA, a pioneering clinical-stage biotech company, has successfully raised an impressive $100 million in funding, aimed at advancing its innovative pipeline of therapeutics for neurodegenerative disorders that currently lack effective treatments.

Specializing in orally bioavailable small molecule drugs, Asceneuron is committed to addressing the urgent medical needs presented by debilitating conditions such as Alzheimer’s disease, Parkinson’s disease, and various orphan tauopathies.

This significant investment underscores the confidence of a renowned syndicate of investors, which includes established entities like Sofinnova Partners, M Ventures, SR One, Johnson & Johnson Innovation – JJDC, Inc.

, and Kurma Partners.

The funding will bolster Asceneuron's ongoing efforts to develop its two lead clinical-stage candidates, which are O-GlcNAcase inhibitors designed to target underlying proteinopathies associated with these diseases.

By advancing these therapeutics through clinical trials, Asceneuron is not only poised to make a substantial impact on patient care but is also paving the way for potential breakthroughs in the treatment landscape for millions worldwide suffering from neurodegenerative disorders.

With this recent influx of capital, Asceneuron is set to accelerate its research efforts and expand its clinical programs, propelling the company towards its mission of bringing much-needed solutions to patients and their families.

For further details, please visit www.asceneuron.com.